Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebellar Neoplasms | 7 | 2022 | 434 | 2.730 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2023 | 2781 | 2.510 |
Why?
|
| Medulloblastoma | 6 | 2022 | 541 | 2.480 |
Why?
|
| Craniospinal Irradiation | 3 | 2023 | 128 | 1.690 |
Why?
|
| Firefighters | 4 | 2016 | 32 | 1.590 |
Why?
|
| Overweight | 5 | 2022 | 485 | 1.580 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2023 | 505 | 1.250 |
Why?
|
| Cancer Survivors | 7 | 2022 | 649 | 1.010 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2022 | 98 | 1.000 |
Why?
|
| Obesity | 6 | 2020 | 2891 | 0.920 |
Why?
|
| Metabolomics | 3 | 2021 | 476 | 0.900 |
Why?
|
| DNA Methylation | 6 | 2020 | 2671 | 0.890 |
Why?
|
| Child | 32 | 2023 | 29067 | 0.840 |
Why?
|
| Weight Loss | 3 | 2016 | 630 | 0.810 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 111 | 0.800 |
Why?
|
| Metabolome | 2 | 2021 | 342 | 0.800 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 49 | 0.770 |
Why?
|
| Genome-Wide Association Study | 8 | 2023 | 2267 | 0.760 |
Why?
|
| Down Syndrome | 2 | 2022 | 223 | 0.750 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 21 | 0.720 |
Why?
|
| Hypothyroidism | 1 | 2021 | 205 | 0.700 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 479 | 0.700 |
Why?
|
| Survivors | 4 | 2022 | 1035 | 0.670 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 333 | 0.650 |
Why?
|
| Neonatal Screening | 1 | 2020 | 165 | 0.640 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 351 | 0.630 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 374 | 0.620 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 124 | 0.590 |
Why?
|
| Weight Gain | 2 | 2019 | 463 | 0.560 |
Why?
|
| Cisplatin | 3 | 2019 | 2432 | 0.550 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2020 | 4556 | 0.540 |
Why?
|
| Child, Preschool | 16 | 2022 | 16213 | 0.530 |
Why?
|
| Ear Diseases | 1 | 2015 | 21 | 0.530 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 601 | 0.520 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 802 | 0.500 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 267 | 0.490 |
Why?
|
| Bone Marrow | 1 | 2021 | 2360 | 0.460 |
Why?
|
| Brain Neoplasms | 4 | 2023 | 4838 | 0.450 |
Why?
|
| Biomarkers | 2 | 2021 | 5055 | 0.440 |
Why?
|
| Male | 30 | 2023 | 123338 | 0.430 |
Why?
|
| Neoplasms | 4 | 2022 | 15180 | 0.410 |
Why?
|
| DNA | 1 | 2020 | 2683 | 0.400 |
Why?
|
| Genome, Human | 1 | 2020 | 1868 | 0.400 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 758 | 0.390 |
Why?
|
| Humans | 43 | 2023 | 262248 | 0.390 |
Why?
|
| Leukemia | 1 | 2020 | 1633 | 0.390 |
Why?
|
| Proton Therapy | 1 | 2021 | 1577 | 0.390 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2023 | 5538 | 0.380 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1350 | 0.380 |
Why?
|
| Health Status | 1 | 2014 | 604 | 0.370 |
Why?
|
| Adolescent | 14 | 2022 | 31239 | 0.350 |
Why?
|
| Genetic Variation | 3 | 2019 | 2089 | 0.340 |
Why?
|
| Hypospadias | 2 | 2020 | 77 | 0.330 |
Why?
|
| Female | 25 | 2023 | 142293 | 0.320 |
Why?
|
| Body Mass Index | 5 | 2020 | 2213 | 0.320 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 316 | 0.280 |
Why?
|
| Fatigue | 3 | 2022 | 1239 | 0.280 |
Why?
|
| Methotrexate | 3 | 2023 | 1002 | 0.250 |
Why?
|
| Incidence | 4 | 2022 | 5713 | 0.240 |
Why?
|
| Creatinine | 2 | 2023 | 538 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2022 | 1041 | 0.230 |
Why?
|
| Infant | 7 | 2022 | 13285 | 0.220 |
Why?
|
| Intelligence | 1 | 2023 | 127 | 0.220 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 64 | 0.220 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 5009 | 0.210 |
Why?
|
| Censuses | 1 | 2022 | 19 | 0.210 |
Why?
|
| Asparaginase | 1 | 2022 | 184 | 0.200 |
Why?
|
| Mucositis | 1 | 2022 | 147 | 0.200 |
Why?
|
| Genotype | 3 | 2020 | 4104 | 0.200 |
Why?
|
| Growth Hormone | 1 | 2021 | 222 | 0.190 |
Why?
|
| Risk Factors | 9 | 2022 | 17622 | 0.190 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 20 | 0.190 |
Why?
|
| Executive Function | 1 | 2021 | 159 | 0.190 |
Why?
|
| Prognosis | 5 | 2022 | 21737 | 0.190 |
Why?
|
| Biliary Atresia | 1 | 2023 | 191 | 0.180 |
Why?
|
| Hypersensitivity | 1 | 2022 | 216 | 0.180 |
Why?
|
| Hodgkin Disease | 2 | 2020 | 1435 | 0.180 |
Why?
|
| Rhabdomyosarcoma | 1 | 2023 | 341 | 0.180 |
Why?
|
| Pancreatitis | 1 | 2022 | 269 | 0.180 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 218 | 0.180 |
Why?
|
| Ikaros Transcription Factor | 1 | 2019 | 54 | 0.170 |
Why?
|
| Diacylglycerol Kinase | 1 | 2019 | 23 | 0.170 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 69 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2023 | 38011 | 0.170 |
Why?
|
| Forecasting | 1 | 2022 | 695 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2023 | 1294 | 0.170 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 146 | 0.170 |
Why?
|
| Sleep | 1 | 2021 | 413 | 0.160 |
Why?
|
| Protons | 1 | 2021 | 473 | 0.160 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 142 | 0.160 |
Why?
|
| Case-Control Studies | 5 | 2023 | 6104 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2020 | 299 | 0.160 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 1397 | 0.150 |
Why?
|
| Residence Characteristics | 1 | 2020 | 349 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 336 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 337 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2020 | 9282 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 311 | 0.150 |
Why?
|
| Leukocyte Count | 1 | 2019 | 683 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 475 | 0.150 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 1175 | 0.150 |
Why?
|
| Adiposity | 2 | 2020 | 238 | 0.150 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 69 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2019 | 1165 | 0.140 |
Why?
|
| Young Adult | 6 | 2022 | 21494 | 0.140 |
Why?
|
| Pilot Projects | 2 | 2022 | 2804 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 678 | 0.140 |
Why?
|
| Hearing Loss | 1 | 2017 | 155 | 0.140 |
Why?
|
| Adult | 11 | 2020 | 78179 | 0.130 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 2207 | 0.130 |
Why?
|
| SEER Program | 1 | 2019 | 1000 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2018 | 291 | 0.130 |
Why?
|
| Directive Counseling | 1 | 2015 | 41 | 0.130 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 772 | 0.130 |
Why?
|
| Computational Biology | 1 | 2021 | 1270 | 0.130 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 328 | 0.120 |
Why?
|
| Neutrophils | 1 | 2019 | 834 | 0.120 |
Why?
|
| Registries | 1 | 2022 | 2188 | 0.120 |
Why?
|
| Waist Circumference | 1 | 2014 | 92 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 499 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 1066 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2019 | 1227 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 3846 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 1668 | 0.110 |
Why?
|
| Prevalence | 2 | 2022 | 3272 | 0.110 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 14288 | 0.110 |
Why?
|
| Age Factors | 3 | 2018 | 5384 | 0.110 |
Why?
|
| Self Report | 1 | 2016 | 776 | 0.110 |
Why?
|
| Recurrence | 1 | 2020 | 4784 | 0.100 |
Why?
|
| Counseling | 1 | 2014 | 383 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 1083 | 0.100 |
Why?
|
| Health Personnel | 1 | 2016 | 632 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 1905 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 2525 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 4337 | 0.090 |
Why?
|
| Pediatrics | 1 | 2019 | 1130 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8225 | 0.090 |
Why?
|
| Middle Aged | 4 | 2019 | 86544 | 0.090 |
Why?
|
| Alleles | 1 | 2015 | 2434 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2020 | 12923 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 5155 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 804 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 10021 | 0.070 |
Why?
|
| United States | 4 | 2018 | 15574 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 4787 | 0.070 |
Why?
|
| CpG Islands | 2 | 2020 | 631 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2019 | 5253 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2020 | 5567 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 6607 | 0.060 |
Why?
|
| Mediator Complex | 1 | 2023 | 69 | 0.060 |
Why?
|
| Hyperbilirubinemia | 1 | 2022 | 77 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 10348 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 338 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 438 | 0.050 |
Why?
|
| Homozygote | 1 | 2023 | 714 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2022 | 435 | 0.050 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 75 | 0.040 |
Why?
|
| Arkansas | 1 | 2019 | 59 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 621 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 853 | 0.040 |
Why?
|
| Exome | 1 | 2023 | 1234 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 2431 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 247 | 0.040 |
Why?
|
| Amino Acids | 1 | 2019 | 727 | 0.030 |
Why?
|
| ROC Curve | 1 | 2019 | 1181 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 257 | 0.030 |
Why?
|
| Parents | 1 | 2023 | 1003 | 0.030 |
Why?
|
| Texas | 2 | 2016 | 6308 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 14913 | 0.030 |
Why?
|
| Tobacco Use | 1 | 2014 | 56 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 2325 | 0.030 |
Why?
|
| Pain | 1 | 2022 | 1667 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 6900 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2014 | 94 | 0.030 |
Why?
|
| Depression | 1 | 2022 | 1730 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2023 | 2811 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 570 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 3076 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 4027 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8885 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 2397 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 3450 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3233 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 4768 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 14561 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 15874 | 0.010 |
Why?
|